Compare IPSC & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | ACB |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 232.3M |
| IPO Year | 2021 | 2016 |
| Metric | IPSC | ACB |
|---|---|---|
| Price | $1.72 | $5.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $4.75 | ★ $4.89 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $2.56 |
| 52 Week High | $2.97 | $6.36 |
| Indicator | IPSC | ACB |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 69.04 |
| Support Level | $1.29 | $3.78 |
| Resistance Level | $1.75 | N/A |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 60.38 | 83.22 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.